Perspective Therapeutics Inc.

About Perspective Therapeutics Inc.

Perspective Therapeutics is a radiopharmaceutical company focused on transforming cancer treatment through targeted alpha particle therapy (TAT). Their mission is to develop image-guided therapies that deliver powerful radiation directly to cancer cells, minimizing damage to healthy tissue and improving patient outcomes.

Products & Services

Pb-based α-Particle Therapy:A revolutionary therapy using Pb-212 to deliver potent alpha radiation directly to cancer cells via high-affinity targeting peptides.

Precision Radiopharmaceuticals:Advanced radiopharmaceuticals designed for precise targeting of tumor cells with minimal off-target effects.

Pb-Specific Chelator (PSC):A proprietary chelator used to conjugate radioisotopes to targeting peptides for effective cancer therapy.

Theranostics Platform:An image-guided platform that confirms tumor target expression before treatment to optimize patient selection and outcomes.

VMT-α-NET:A candidate for neuroendocrine tumors and other SSTR2-expressing tumors, currently in clinical evaluation.

VMT01/02:Therapy and imaging for melanoma targeting MC1R, with ongoing trials as monotherapy and in combination with nivolumab.

PSV359:A therapy targeting FAP-α for multiple solid tumors, currently enrolling patients in Phase 1/2a studies.

Pre-Targeting Platform:An innovative platform under evaluation for multiple solid tumors.

VMT-α-NET (SSTR2) for Neuroendocrine Tumors

VMT01 (MC1R) for Melanoma

PSV359 (FAP-α) for Solid Tumors

PSV594 (CCK2R) for Solid Tumors

Specialties

Targeted Alpha Particle Therapy Image-Guided Theranostics Radiopharmaceutical Development Cancer Treatment Pb-212 Based Therapies Targeted alpha-particle therapies (TATs) Image-guided theranostics Pb-203/Pb-212 isotope pair radiopharmaceuticals Precision radiopharmaceutical manufacturing and logistics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 175000000 MR: - FA: $175 million FAN: 175000000	D: 2026-02-02 FD: 2026-02-02	8 investors
2	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 80000000 MR: - FA: approximately $80 million FAN: 80000000	D: 2024-05-24 FD: 2024-05-24	4 investors
3	RT: Private Placement T: - FT: Private Placement	A: 87400000 MR: - FA: 87.4 million FAN: 87400000	D: 2024-03-04 FD: 2024-03-04	1 investors
4	RT: Public Offering and Private Placement T: - FT: Public Offering and Private Placement	A: 89800000 MR: - FA: $89.8 million FAN: 89800000	D: 2024-01-22 FD: 2024-01-22	3 investors
5	RT: Public Offering and Private Placement T: - FT: Public Offering and Private Placement	A: 80800000 MR: - FA: $80.8 million FAN: 80800000	D: 2024-01-18 FD: 2024-01-18	2 investors

Underwritten Offering Latest

2026-02-02

$175.0M

8 investors (Pro only)

Underwritten Offering 2024-05-24

$80.0M

Private Placement 2024-03-04

$87.4M

View 4 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Thijs Spoor

Chief Executive Officer

J

Joel Sendek

Chief Financial Officer

M

Markus Puhlmann

Chief Medical Officer

M

Michael K. Schultz

Chief Science Officer & Co-Founder

A

Amos Hedt

Chief Business Strategy Officer

J

Jonathan Hunt

Chief Accounting Officer

View 22 more team members with Pro

Unlock Full Team Directory

Recent News